National Lipid Association asks members to complete survey on PCSK9 inhibitors
The National Lipid Association (NLA) is asking members to complete an online survey regarding challenges patients face in getting access to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.
The NLA said prescribers and non-prescribers could complete the survey by Sept. 30.
The FDA has approved two PCSK9 inhibitors: alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) and evolocumab (Repatha, Amgen).
The injectable medications have been shown to lower low-density lipoprotein cholesterol, but trials are ongoing to determine if the drugs have an effect on cardiovascular mortality and morbidity.
Sales of the medications, which cost more than $14,000 per year, have fallen short of expectations since they were approved last summer.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.